BÜHLMANN Laboratories AG

QuidelOrtho and BÜHLMANN Launch Rapid Gastrointestinal Biomarker Assays for IBD and Pancreatic Insufficiency Diagnosis

- QuidelOrtho Corporation and BÜHLMANN Laboratories AG have announced the availability of fCAL turbo and fPELA turbo assays on VITROS Systems for rapid gastrointestinal biomarker testing. - The fCAL turbo assay aids in diagnosing inflammatory bowel disease and differentiating it from irritable bowel syndrome, while the fPELA turbo assay helps determine pancreatic insufficiency. - Both particle-enhanced turbidimetric immunoassays deliver results in less than 10 minutes and feature 90-day on-analyzer stability with simplified sample preparation using CALEX Cap technology. - The collaboration addresses the growing demand for non-invasive diagnostic tools and cost-effective healthcare solutions in gastrointestinal and pancreatic health management.